RCKT Quote, Financials, Valuation and Earnings

Inogen has a net margin of -- compared to Rocket Pharmaceuticals's net margin of -6.71%. Rocket Pharmaceuticals's return on equity of -- beat Inogen's return on equity of -26.33%.

Rocket Pharmaceuticals has a consensus price target of $43.13, signalling upside risk potential of 287.19%. On the other hand Inogen has an analysts' consensus of -- which suggests that it could grow by 4.71%. Given that Rocket Pharmaceuticals has higher upside potential than Inogen, analysts believe Rocket Pharmaceuticals is more attractive than Inogen.

Rocket Pharmaceuticals has a beta of 1.007, which suggesting that the stock is 0.72700000000001% more volatile than S&P 500. In comparison Inogen has a beta of 1.025, suggesting its more volatile than the S&P 500 by 2.462%.

Rocket Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rocket Pharmaceuticals pays -- of its earnings as a dividend. Inogen pays out -- of its earnings as a dividend.

Rocket Pharmaceuticals quarterly revenues are --, which are smaller than Inogen quarterly revenues of $88.8M. Rocket Pharmaceuticals's net income of -$66.7M is lower than Inogen's net income of -$6M. Notably, Rocket Pharmaceuticals's price-to-earnings ratio is -- while Inogen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rocket Pharmaceuticals is -- versus 0.68x for Inogen. Usually stocks with elevated PS ratios are considered overvalued.

Marinus Pharmaceuticals has a net margin of -- compared to Rocket Pharmaceuticals's net margin of -283.63%. Rocket Pharmaceuticals's return on equity of -- beat Marinus Pharmaceuticals's return on equity of -1150.43%.

Rocket Pharmaceuticals has a consensus price target of $43.13, signalling upside risk potential of 287.19%. On the other hand Marinus Pharmaceuticals has an analysts' consensus of $1.07 which suggests that it could grow by 98.64%. Given that Rocket Pharmaceuticals has higher upside potential than Marinus Pharmaceuticals, analysts believe Rocket Pharmaceuticals is more attractive than Marinus Pharmaceuticals.

Rocket Pharmaceuticals has a beta of 1.007, which suggesting that the stock is 0.72700000000001% more volatile than S&P 500. In comparison Marinus Pharmaceuticals has a beta of 1.035, suggesting its more volatile than the S&P 500 by 3.471%.

Rocket Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Marinus Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rocket Pharmaceuticals pays -- of its earnings as a dividend. Marinus Pharmaceuticals pays out -- of its earnings as a dividend.

Rocket Pharmaceuticals quarterly revenues are --, which are smaller than Marinus Pharmaceuticals quarterly revenues of $8.5M. Rocket Pharmaceuticals's net income of -$66.7M is lower than Marinus Pharmaceuticals's net income of -$24.2M. Notably, Rocket Pharmaceuticals's price-to-earnings ratio is -- while Marinus Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rocket Pharmaceuticals is -- versus 0.97x for Marinus Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Rocket Pharmaceuticals's net margin of -49.65%. Rocket Pharmaceuticals's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Rocket Pharmaceuticals has a consensus price target of $43.13, signalling upside risk potential of 287.19%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 434.43%. Given that NovaBay Pharmaceuticals has higher upside potential than Rocket Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than Rocket Pharmaceuticals.

Rocket Pharmaceuticals has a beta of 1.007, which suggesting that the stock is 0.72700000000001% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Rocket Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rocket Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Rocket Pharmaceuticals quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Rocket Pharmaceuticals's net income of -$66.7M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Rocket Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rocket Pharmaceuticals is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Spyre Therapeutics has a net margin of -- compared to Rocket Pharmaceuticals's net margin of --. Rocket Pharmaceuticals's return on equity of -- beat Spyre Therapeutics's return on equity of --.

Rocket Pharmaceuticals has a consensus price target of $43.13, signalling upside risk potential of 287.19%. On the other hand Spyre Therapeutics has an analysts' consensus of $43.14 which suggests that it could grow by 161.02%. Given that Rocket Pharmaceuticals has higher upside potential than Spyre Therapeutics, analysts believe Rocket Pharmaceuticals is more attractive than Spyre Therapeutics.

Rocket Pharmaceuticals has a beta of 1.007, which suggesting that the stock is 0.72700000000001% more volatile than S&P 500. In comparison Spyre Therapeutics has a beta of 2.860, suggesting its more volatile than the S&P 500 by 185.983%.

Rocket Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spyre Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rocket Pharmaceuticals pays -- of its earnings as a dividend. Spyre Therapeutics pays out -- of its earnings as a dividend.

Rocket Pharmaceuticals quarterly revenues are --, which are smaller than Spyre Therapeutics quarterly revenues of --. Rocket Pharmaceuticals's net income of -$66.7M is higher than Spyre Therapeutics's net income of -$69M. Notably, Rocket Pharmaceuticals's price-to-earnings ratio is -- while Spyre Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rocket Pharmaceuticals is -- versus 771.72x for Spyre Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.